ArticleContemporary oncology (Poznan, Poland)2022
Examining the use of abdominal compression in stereotactic body radiotherapy for liver metastases - a single center's experience of 10 years.
Article in Contemporary oncology (Poznan, Poland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Stereotactic body radiotherapy (SBRT) with abdominal compression (AC) stands out due to the high tolerance and ease of application in the treatment of liver metastases. The present study aimed to report the safety and efficacy of the AC technique with 10-year follow-up outcomes. Materials and methods: A retrospective review was made of patients in the database who had liver metastases, who did not undergo surgery or any other ablative approach for metastases, and who underwent SBRT with AC. In-field local control (ifLC) and toxicity were evaluated as primary endpoints. Results: The study examined 79 patients who underwent SBRT with AC between 2012 and 2021. Colorectal adenocarcinoma was the most common type of primary tumor ( Conclusions: SBRT with AC is a well-tolerated and effective treatment modality for patients with liver metastases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.